|
1
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Beltran A, Scarpelli M, Montironi R
and Kirkali Z: 2004 WHO classification of the renal tumors of the
adults. Eur Urol. 49:798–805. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brodaczewska KK, Szczylik C, Fiedorowicz
M, Porta C and Czarnecka AM: Choosing the right cell line for renal
cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rydzanicz M, Wrzesinski T, Bluyssen HA and
Wesoly J: Genomics and epigenomics of clear cell renal cell
carcinoma: Recent developments and potential applications. Cancer
Lett. 341:111–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miyajima A, Kosaka T, Kikuchi E and Oya M:
Renin-angiotensin system blockade: Its contribution and
controversy. Int J Urol. 22:721–730. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wegman-Ostrosky T, Soto-Reyes E,
Vidal-Millán S and Sánchez-Corona J: The renin-angiotensin system
meets the hallmarks of cancer. J Renin Angiotensin Aldosterone
Syst. 16:227–233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Derosa L, Izzedine H, Albiges L and
Escudier B: Hypertension and angiotensin system inhibitors in
patients with metastatic renal cell carcinoma. Oncol Rev.
10:2982016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin G, Yan C and Berk BC: Angiotensin II
signaling pathways mediated by tyrosine kinases. Int J Biochem Cell
Biol. 35:780–783. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Donoghue M, Hsieh F, Baronas E, Godbout K,
Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan
R, et al: A novel angiotensin-converting enzyme-related
carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.
Circ Res. 87:E1–E9. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tipnis SR, Hooper NM, Hyde R, Karran E,
Christie G and Turner AJ: A human homolog of angiotensin-converting
enzyme. Cloning and functional expression as a
captopril-insensitive carboxypeptidase. J Biol Chem.
275:33238–33243. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhuo JL and Li XC: New insights and
perspectives on intrarenal renin-angiotensin system: Focus on
intracrine/intracellular angiotensin II. Peptides. 32:1551–1565.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Norwood VF, Craig MR, Harris JM and Gomez
RA: Differential expression of angiotensin II receptors during
early renal morphogenesis. Am J Physiol. 272:R662–R668.
1997.PubMed/NCBI
|
|
14
|
Arendshorst WJ, Brännström K and Ruan X:
Actions of angiotensin II on the renal microvasculature. J Am Soc
Nephrol. 10 Suppl 11:S149–S161. 1999.PubMed/NCBI
|
|
15
|
Matsubara H, Sugaya T, Murasawa S, Nozawa
Y, Mori Y, Masaki H, Maruyama K, Tsutumi Y, Shibasaki Y, Moriguchi
Y, et al: Tissue-specific expression of human angiotensin II AT1
and AT2 receptors and cellular localization of subtype mRNAs in
adult human renal cortex using in situ hybridization. Nephron.
80:25–34. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldfarb DA, Diz DI, Tubbs RR, Ferrario CM
and Novick AC: Angiotensin II receptor subtypes in the human renal
cortex and renal cell carcinoma. J Urol. 151:208–213. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chatterjee PK, Weerackody RP, Mistry SK,
Hawksworth GM and McLay JS: Selective antagonism of the AT1
receptor inhibits angiotensin II stimulated DNA and protein
synthesis in primary cultures of human proximal tubular cells.
Kidney Int. 52:699–705. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao Z, Kelly DJ, Cox A, Casley D, Forbes
JM, Martinello P, Dean R, Gilbert RE and Cooper ME: Angiotensin
type 2 receptor is expressed in the adult rat kidney and promotes
cellular proliferation and apoptosis. Kidney Int. 58:2437–2351.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dolley-Hitze T, Jouan F, Martin B, Mottier
S, Edeline J, Moranne O, Le Pogamp P, Belaud-Rotureau MA, Patard
JJ, Rioux-Leclercq N and Vigneau C: Angiotensin-2 receptors (AT1-R
and AT2-R), new prognostic factors for renal clear-cell carcinoma?
Br J Cancer. 103:1698–1705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gonzalez-Villalobos RA, Shen XZ, Bernstein
EA, Janjulia T, Taylor B, Giani JF, Blackwell WL, Shah KH, Shi PD,
Fuchs S and Bernstein KE: Rediscovering ACE: Novel insights into
the many roles of the angiotensin-converting enzyme. J Mol Med
(Berl). 91:1143–1154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krege JH, John SW, Langenbach LL, Hodgin
JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA and Smithies O:
Male-female differences in fertility and blood pressure in
ACE-deficient mice. Nature. 375:146–148. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin C, Datta V, Okwan-Duodu D, Chen X,
Fuchs S, Alsabeh R, Billet S, Bernstein KE and Shen XZ:
Angiotensin-converting enzyme is required for normal myelopoiesis.
FASEB J. 25:1145–1155. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chappell MC: Emerging evidence for a
functional angiotensin-converting enzyme 2-angiotensin-(1–7)-MAS
receptor axis: More than regulation of blood pressure?
Hypertension. 50:596–599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takada Y, Hiwada K, Yokoyama M, Ochi K,
Takeuchi M and Kokubu T: Angiotensin converting enzyme. A possible
histologic indicator for human renal cell carcinoma. Cancer.
56:130–133. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Larrinaga G, Pérez I, Sanz B, Blanco L,
López JI, Cándenas ML, Pinto FM, Gil J, Irazusta J and Varona A:
Angiotensin-converting enzymes (ACE and ACE2) are downregulated in
renal tumors. Regul Pept. 165:218–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Usmani BA, Janeczko M, Shen R, Mazumdar M,
Papandreou CN and Nanus DM: Analysis of the insertion/deletion
polymorphism of the human angiotensin converting enzyme (ACE) gene
in patients with renal cancer. Br J Cancer. 82:550–552.
2000.PubMed/NCBI
|
|
27
|
de Martino M, Klatte T, Schatzl G, Waldert
M, Remzi M, Haitel A, Kramer G and Marberger M: Insertion/deletion
polymorphism of angiotensin I-converting enzyme gene is linked with
chromophobe renal cell carcinoma. Urology. 77:1005.e9–1005.e13.
2011. View Article : Google Scholar
|
|
28
|
van der Knaap R, Siemes C, Coebergh JW,
van Duijn CM, Hofman A and Stricker BH: Renin-angiotensin system
inhibitors, angiotensin I-converting enzyme gene insertion/deletion
polymorphism and cancer: The Rotterdam Study. Cancer. 112:748–757.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deckers IA, van den Brandt PA, van
Engeland M, van Schooten FJ, Godschalk RW, Keszei AP and Schouten
LJ: Polymorphisms in genes of the renin-angiotensin-aldosterone
system and renal cell cancer risk: Interplay with hypertension and
intakes of sodium, potassium and fluid. Int J Cancer.
136:1104–1116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Andreotti G, Boffetta P, Rosenberg PS,
Berndt SI, Karami S, Menashe I, Yeager M, Chanock SJ, Zaridze D,
Matteev V, et al: Variants in blood pressure genes and the risk of
renal cell carcinoma. Carcinogenesis. 31:614–620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kohara K, Brosnihan KB and Ferrario CM:
Angiotensin(1–7) in the spontaneously hypertensive rat. Peptides.
14:883–891. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu T, Miller AG, Deliyanti D, Berka DR,
Agrotis A, Campbell DJ and Wilkinson-Berka JL: Prorenin stimulates
a pro-angiogenic and pro-inflammatory response in retinal
endothelial cells and an M1 phenotype in retinal microglia. Clin
Exp Pharmacol Physiol. 42:537–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shibayama Y, Fujimori T, Nguyen G, Hirose
T, Totsune K, Ichihara A, Kitada K, Nakano D, Kobori H, Kohno M, et
al: (Pro)renin receptor is crucial for Wnt/β-catenin-dependent
genesis of pancreatic ductal adenocarcinoma. Sci Rep. 5:88542015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Trask AJ and Ferrario CM:
Angiotensin-(1–7): pharmacology and new perspectives in
cardiovascular treatments. Cardiovasc Drug Rev. 25:162–174. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yacoub R and Campbell KN: Inhibition of
RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 8:29–40.
2015.PubMed/NCBI
|
|
36
|
Montana V and Sontheimer H: Bradykinin
promotes the chemotactic invasion of primary brain tumors. J
Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Williams RN, Parsons SL, Morris TM,
Rowlands BJ and Watson SA: Inhibition of matrix metalloproteinase
activity and growth of gastric adenocarcinoma cells by an
angiotensin converting enzyme inhibitor in in vitro and murine
models. Eur J Surg Oncol. 31:1042–1050. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
de Groot-Besseling RR, Ruers TJ, van
Kraats AA, Poelen GJ, Ruiter DJ, de Waal RM and Westphal JR:
Anti-tumor activity of a combination of plasminogen activator and
captopril in a human melanoma xenograft model. Int J Cancer.
112:329–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
McMurray J and Chopra M: Influence of ACE
inhibitors on free radicals and reperfusion injury: Pharmacological
curiosity or therapeutic hope? Br J Clin Pharmacol. 31:373–379.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng S, Yang Y, Song R, Yang X, Liu H, Ma
Q, Yang L, Meng R, Tao T, Wang S and He J: Ang-(1–7) promotes the
migration and invasion of human renal cell carcinoma cells via
Mas-mediated AKT signaling pathway. Biochem Biophys Res Commun.
460:333–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Esteban V, Heringer-Walther S,
Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S,
Egido J, Schultheiss HP, Ruiz-Ortega M and Walther T:
Angiotensin-(1–7) and the g protein-coupled receptor MAS are key
players in renal inflammation. PLoS One. 4:e54062009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y,
Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration
and invasion of A549 human lung adenocarcinoma cells through
inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol
Rep. 27:783–790. 2012.PubMed/NCBI
|
|
43
|
Soto-Pantoja DR, Menon J, Gallagher PE and
Tallant EA: Angiotensin-(1–7) inhibits tumor angiogenesis in human
lung cancer xenografts with a reduction in vascular endothelial
growth factor. Mol Cancer Ther. 8:1676–1683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gallagher PE and Tallant EA: Inhibition of
human lung cancer cell growth by angiotensin-(1–7). Carcinogenesis.
25:2045–2052. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mukai H, Fitzgibbon WR, Bozeman G,
Margolius HS and Ploth DW: Bradykinin B2 receptor antagonist
increases chloride and water absorption in rat medullary collecting
duct. Am J Physiol. 271:R352–R360. 1996.PubMed/NCBI
|
|
46
|
Bagaté K, Grima M, Imbs JL, Jong WD,
Helwig JJ and Barthelmebs M: Signal transduction pathways involved
in kinin B(2) receptor-mediated vasodilation in the rat isolated
perfused kidney. Br J Pharmacol. 132:1735–1742. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
El-Dahr SS, Dipp S and Baricos WH:
Bradykinin stimulates the ERK->Elk-1->Fos/AP-1 pathway in
mesangial cells. Am J Physiol. 275:F343–F352. 1998.PubMed/NCBI
|
|
48
|
Moodley R, Snyman C, Odhav B and Bhoola
KD: Visualisation of transforming growth factor-beta 1, tissue
kallikrein, and kinin and transforming growth factor-beta receptors
on human clear-cell renal carcinoma cells. Biol Chem. 386:375–382.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kramarenko II, Morinelli TA, Bunni MA,
Raymond JR Sr and Garnovskaya MN: The bradykinin B(2) receptor
induces multiple cellular responses leading to the proliferation of
human renal carcinoma cell lines. Cancer Manag Res. 4:195–205.
2012.PubMed/NCBI
|
|
50
|
Lever AF, Hole DJ, Gillis CR, McCallum IR,
McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and
Robertson JW: Do inhibitors of angiotensin-I-converting enzyme
protect agains risk of cancer? Lancet. 352:179–184. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yoon C, Yang HS, Jeon I, Chang Y and Park
SM: Use of angiotensin-converting-enzyme inhibitors or
angiotensin-receptor blockers and cancer risk: A meta-analysis of
observational studies. CMAJ. 183:E1073–E1084. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fryzek JP, Poulsen AH, Johnsen SP,
McLaughlin JK, Sørensen HT and Friis S: A cohort study of
antihypertensive treatments and risk of renal cell cancer. Br J
Cancer. 92:1302–1306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chin HJ, Oh SW, Goo HS, Oh J, Noh JW, Cho
JT, Na KY, Kim S and Chae DW: Members of The PREMIER Group: Effect
of RAAS inhibition on the incidence of cancer and cancer mortality
in patients with glomerulonephritis. J Korean Med Sci. 26:59–66.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wysocki PJ, Kwiatkowska EP, Kazimierczak
U, Suchorska W, Kowalczyk DW and Mackiewicz A: Captopril, an
angiotensin-converting enzyme inhibitor, promotes growth of
immunogenic tumors in mice. Clin Cancer Res. 12:4095–4102. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hii SI, Nicol DL, Gotley DC, Thompson LC,
Green MK and Jonsson JR: Captopril inhibits tumour growth in a
xenograft model of human renal cell carcinoma. Br J Cancer.
77:880–883. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Araujo WF, Naves MA, Ravanini JN, Schor N
and Teixeira VP: Renin-angiotensin system (RAS) blockade attenuates
growth and metastatic potential of renal cell carcinoma in mice.
Urol Oncol. 33:389.e1–e7. 2015. View Article : Google Scholar
|
|
57
|
McKay RR, Rodriguez GE, Lin X, Kaymakcalan
MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R and Choueiri
TK: Angiotensin system inhibitors and survival outcomes in patients
with metastatic renal cell carcinoma. Clin Cancer Res.
21:2471–2479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tatokoro M, Fujii Y, Kawakami S, Saito K,
Koga F, Matsuoka Y, Iimura Y, Masuda H and Kihara K: Phase-II trial
of combination treatment of interferon-α, cimetidine,
cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor
(I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci.
102:137–143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Miyajima A, Yazawa S, Kosaka T, Tanaka N,
Shirotake S, Mizuno R, Kikuchi E and Oya M: Prognostic impact of
renin-angiotensin system blockade on renal cell carcinoma after
surgery. Ann Surg Oncol. 22:3751–3759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Keizman D, Huang P, Eisenberger MA, Pili
R, Kim JJ, Antonarakis ES, Hammers H and Carducci MA: Angiotensin
system inhibitors and outcome of sunitinib treatment in patients
with metastatic renal cell carcinoma: A retrospective examination.
Eur J Cancer. 47:1955–1961. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Izzedine H, Derosa L, Le Teuff G, Albiges
L and Escudier B: Hypertension and angiotensin system inhibitors:
Impact on outcome in sunitinib-treated patients for metastatic
renal cell carcinoma. Ann Oncol. 26:1128–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hamnvik OP, Choueiri TK, Turchin A, McKay
RR, Goyal L, Davis M, Kaymakcalan MD and Williams JS: Clinical risk
factors for the development of hypertension in patients treated
with inhibitors of the VEGF signaling pathway. Cancer. 121:311–319.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sorich MJ, Kichenadasse G, Rowland A,
Woodman RJ and Mangoni AA: Angiotensin system inhibitors and
survival in patients with metastatic renal cell carcinoma treated
with VEGF-targeted therapy: A pooled secondary analysis of clinical
trials. Int J Cancer. 138:2293–2299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Penttila P, Rautiola J, Poussa T, Peltola
K and Bono P: Angiotensin inhibitors as treatment of
Sunitinib/Pazopanib-induced hypertension in metastatic renal cell
carcinoma. Clin Genitourin Cancer. 15:384–390.e3. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Huillard O, Xylinas E, Peyromaure M,
Alexandre J and Goldwasser F: Angiotensin system inhibitors in
renal cell carcinoma-letter. Clin Cancer Res. 22:5242016.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chobanian AV, Bakris GL, Black HR, Cushman
WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright
JT Jr, et al: Seventh report of the Joint National Committee on
prevention, detection, evaluation, and treatment of high blood
pressure. Hypertension. 42:1206–1252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rini BI, Cohen DP, Lu DR, Chen I,
Hariharan S, Gore ME, Figlin RA, Baum MS and Motzer RJ:
Hypertension as a biomarker of efficacy in patients with metastatic
renal cell carcinoma treated with sunitinib. J Natl Cancer Inst.
103:763–773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Robinson ES, Khankin EV, Choueiri TK,
Dhawan MS, Rogers MJ, Karumanchi SA and Humphreys BD: Supression of
the nitric oxide pathway in metastatic renal cell carcinoma
patients receiving vascular endothelial growth factor-signaling
inhibitors. Hypertension. 56:1131–1136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gupta R and Maitland ML: Sunitinib,
hypertension, and heart failure: A model for kinase
inhibitor-mediated cardiotoxicity. Curr Hypertens Rep. 13:430–435.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kappers MH, van Esch JH, Sluiter W,
Sleijfer S, Danser AH and van den Meiracker AH: Hypertension
induced by the tyrosine kinase inhibitor sunitinib is associated
with increased circulating endothelin-1 levels. Hypertension.
56:675–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Veronese ML, Mosenkis A, Flaherty KT,
Gallagher M, Stevenson JP, Townsend RR and O'Dwyer PJ: Mechanisms
of hypertension associated with BAY 43–9006. J Clin Oncol.
24:1363–1369. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Curwen JO, Musgrove HL, Kendrew J,
Richmond GH, Ogilvie DJ and Wedge SR: Inhibition of vascular
endothelial growth factor-a signaling induces hypertension:
Examining the effect of cediranib (recentin; AZD2171) treatment on
blood pressure in rat and the use of concomitant antihypertensive
therapy. Clin Cancer Res. 14:3124–3131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Siddiqui AJ, Mansson-Broberg A, Gustafsson
T, Grinnemo KH, Dellgren G, Hao X, Fischer H and Sylvén C:
Antagonism of the renin-angiotensin system can counteracts cardiac
angiogenic vascular endothelial growth factor gene therapy and
myocardial angiogenesis in normal heart. Am J Hyprtens.
18:1347–1352. 2005. View Article : Google Scholar
|
|
74
|
Agabiti-Rosei E: Structural and functional
changes of the microcirculation in hypertension: Influence of
pharmacological therapy. Drugs. 63:19–29. 2003.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Szmit S, Langiewicz P, Zlnierek J,
Nurzyński P, Zaborowska M, Filipiak KJ, Opolski G and Szczylik C:
Hypertension as a predictive factor for survival outcomes in
patients with metastatic renal cell carcinoma treated with
sunitinib after progression on cytokines. Kidney Blood Press Res.
35:18–25. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhu X, Stergiopoulos K and Wu S: Risk of
hypertension and renal dysfunction with an angiogenesis inhibitor
sunitinib: Systematic review and meta-analysis. Acta Oncol.
48:9–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Nagasawa T, Khan Hye MA and Imig JD:
Captopril attenuates hypertension and renal injury induced by the
vascular endothelial growth factor inhibitor sorafenib. Clin Exp
Pharmacol Physiol. 39:454–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lankhorst S, Kappers MH, van Esch JH,
Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH and van
den Meiracker AH: Treatment of hypertension and renal injury
induced by the angiogenesis inhibitor sunitinib: Preclinical study.
Hypertension. 64:1282–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
